← All trials
NCT06416735
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2018
- Primary completion
- Jul 20, 2020
- Completion date
- Jul 20, 2020
- First posted
- May 16, 2024
- Last posted
- May 16, 2024
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vita-Salute University of Milano. ItalyLead sponsor
- Vita-Salute University of Milano. ItalySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.